Leadership: Page 7
-
Q&A // Biotech Spotlight
Why AbbVie’s former president has high hopes for this Flagship-backed biotech
The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.
By Karissa Waddick • Aug. 7, 2023 -
New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine
A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.
By Michael Gibney • Aug. 3, 2023 -
Trendline
Commercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Biogen’s layoffs are the latest in an industrywide slip
Over 100 biotech companies so far this year have cut staff due to persistent funding challenges.
By Karissa Waddick • July 26, 2023 -
Q&A
A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here
Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.
By Taren Grom and Meagan Parrish • July 20, 2023 -
Profile
What the 2014 Ebola outbreak taught this biotech CEO about persuasion
A former WHO epidemiologist is applying lessons learned during the Ebola epidemic to her work leading a company at the forefront of women’s health: the reproductive microbiome.
By Alexandra Pecci • July 18, 2023 -
Making Moves
Flagship, PhRMA prioritize experience in hot summer exec changes
With major projects brewing at both organizations, these new leaders will hit the ground running.
By Karissa Waddick • July 14, 2023 -
Q&A // First 90 Days
A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus
After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through the clinic.
By Alexandra Pecci • July 11, 2023 -
The stories you’ve read the most in 2023 (so far)
From staff shortages to presidential candidates and the M&A outlook, here are our most-read stories from the first half of the year.
By PharmaVoice Staff • July 3, 2023 -
A pharma summer — how leaders unwind and recharge their teams in the warmer months
Vacation is calling, but so are patients. Here's how the industry adjusts in the summer.
By Michael Gibney • June 30, 2023 -
Q&A
How Sanofi is taking a ‘creative’ approach to dealmaking
Dr. Monika Vnuk, SVP of global partnering and business development, is setting her sights on out-of-the-box partnerships.
By Taren Grom • June 23, 2023 -
10 years proud: Pharma’s top companies for LGBTQ+ inclusivity
These six Big Pharma companies have ranked among the best places to work for LGTBQ+ equality by the Human Rights Campaign Foundation for over 10 years. Here’s why.
By Karissa Waddick , Taren Grom • June 22, 2023 -
Q&A
DIA’s chief exec is on a mission to grow its footprint across healthcare
Marwan Fathallah came onboard earlier this year to lead the organization into an era of change.
By Michael Gibney • June 22, 2023 -
Podcast
Woman of the Week: Stealth BioTherapeutics’ Reenie McCarthy
How the CEO navigated a regulatory odyssey to bring the company’s lead program for an ultra-rare disease to a fast track approval.
By Taren Grom • June 21, 2023 -
Profile
Duty to serve: an Army officer’s unexpected path to GSK
How Court Horncastle, SVP, business unit head of the anti-infective and respiratory team at GSK, applies lessons from combat to his work in antibiotics.
By Alexandra Pecci • June 21, 2023 -
Opinion
Shaking up pharma: Change that leaders would like to see
Industry execs give voice to the “game changers” they believe would have the greatest impact on the healthcare ecosystem for all.
By Taren Grom • June 16, 2023 -
Podcast
Woman of the Week: Gamida Cell’s Abbey Jenkins
The first-time CEO discusses the lessons she has learned since taking the role last year and how she’s pivoting the company into a commercial entity.
By Taren Grom • June 14, 2023 -
The ingredients of a successful biopharma collaboration
Collaboration is important along the entire spectrum and lifecycle of biopharma, and finding an effective partner is harder than it sounds.
By Michael Gibney • June 13, 2023 -
Yes, biopharma still has a reputation problem. These leaders are looking for solutions.
Negative news is breaking down the public’s perception of the biopharma industry — but leaders around the industry have some ideas to fix it.
By Michael Gibney • June 8, 2023 -
Podcast
Woman of the Week: Marinus Pharmaceuticals’ Christy Shafer
The chief commercial officer shares how the company “beat the odds” to bring a rare disease drug to market.
By Taren Grom • June 7, 2023 -
Q&A
Ranking reveals biopharma’s most innovative companies
IDEA Pharma’s 12th index finds that Pfizer and AstraZeneca reign supreme again.
By Taren Grom • June 7, 2023 -
Profile
BIO’s CEO digs into the hot-button issues facing the industry
Rachel King took the reins at BIO during a rocky time. Now, after steadying the ship, she’s brought the trade association’s focus back to the industry’s most pressing priorities.
By Alexandra Pecci • June 5, 2023 -
Janssen and Legend’s longtime collaboration lands a CAR-T win at ASCO
A partnership going on six years between the pharma giant and the Chinese biotech is showing that their CAR-T cell therapy for multiple myeloma is highly effective.
By Michael Gibney • June 5, 2023 -
Opinion
A key to ‘winning’ in today’s market — and other trends pharma leaders are tracking
Healthcare pros share the market drivers they believe are having the biggest impact on the industry.
By Taren Grom • June 2, 2023 -
Q&A
How Takeda finds the hottest new science to fuel its oncology work
Takeda's president of the global oncology business unit is always "scanning the horizon" for the partnerships that will drive the next big innovations.
By Michael Gibney • June 1, 2023 -
Podcast
Woman of the Week: Mirati Therapeutics’ Laurie Stelzer
With the recent approval of Krazati, the biotech veteran is guiding Mirati into its next phase as a commercial organization.
By Taren Grom • May 31, 2023